ARDX 4.92 (+2.71%)
US0396971071BiotechnologyBiotechnology

Ardelyx (ARDX) Stock Highlights

4.92 | +2.71%
2024-11-21 03:37:38
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.

Statistics

Range Today
4.68 4.96
Volume Today 4.35M
Range 1 Year
4.06 10.13
Volume 1 Year 1.27B
Range 3 Year
0.49 10.13
Volume 3 Year 4.86B
Range 10 Year
0.49 35.48
Volume 10 Year 6.49B

Highlights

Market Capitalization 1.2B (small)
Floating Shares 231.38M
Current Price 4.92
Price To Earnings -18.03
Price To Revenue 4.52
Price To Book 7.59
Earnings Per Share -0.32
Payout Ratio 0%

Performance

Latest +2.71%
1 Month -15.17%
3 Months -17.73%
6 Months -36.92%
1 Year +13.36%
3 Years +396.97%
5 Years -29.71%
10 Years -76.41%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.